Comparison of the Effects Suprascapular Nerve Block and Intra-articular Shoulder Injection

NCT05909462 | Completed

• 5 other identifiers: 2023-56Deniz İpekMehmet YalvaçMurat DoğanAbdulrahim Dündar
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

Objectives: In this study, we aimed to compare the efficacy of ultrasonography-guided suprascapular nerve block and intra-articular shoulder injection treatment in terms of joint range of motion, pain and functional status in patients with adhesive capsulitis (AC). Patients and Methods: 60 patients AC were included in our study. The patients were randomized into two groups according to the sealed envelope method. In the evaluation of the patients before the injection, age, gender, body mass index (BMI), occupation, education, duration of complaint, symptomatic side and dominant hand information were recorded. In the first group, 2 ml of 40 mg triamcinolone acetonide and 4 ml of 1% lidocaine injection were mixed with the posterior approach method into the shoulder joint under the guidance of ultrasonography (USG). The second group underwent suprascapular nerve block (SSNB) injection with 2 ml of 40 mg triamcinolone acetonide and 4 ml of 1% lidocaine under USG guidance. Shoulder range of motion (ROM), visual analog scale (VAS) scores and Shoulder Pain and Disability Index (SPADI) scores were compared before the injection, on the tenth day after the injection and at the third month after the injection. Conclusion: As a result of our study, although it was observed that both methods provided improvement in the treatment process, the significant improvement in the SSNB group indicates that it is a more reliable treatment method in AC treatment.

Conditions

Adhesive Capsulitis

Keywords

Adhesive capsulitis; suprascapular nerve block; intra-articular shoulder injection; ultrasonography.

Outcome Measures

Primary Outcomes (2)

• Changes from baseline in pain on The Shoulder Pain and Disability Index (SPADI) at the tenth day after the injection

  SPADI is a valid and reliable questionnaire used in shoulder disorders. Possible scores range from 0 (no pain) to 100 (severe shoulder pain)= Changes tenth day after the injection-baseline

  baseline and on the tenth day after the injection

• The effectiveness of suprascapular nerve block on pain is higher than intra-articular

  Shoulder Pain and Disability Index

  between before treatment and on the tenth day after the injection

Study Arms (2)

suprascapular verve block

EXPERIMENTAL

2 ml of 40 mg triamcinolone acetonide and 4 ml of 1% lidocaine

Drug: 2 ml of 40 mg triamcinolone acetonide and 4 ml of 1% lidocaine

intraarticular shoulder injection

EXPERIMENTAL

2 ml of 40 mg triamcinolone acetonide and 4 ml of 1% lidocaine

Drug: 2 ml of 40 mg triamcinolone acetonide and 4 ml of 1% lidocaine

Interventions

2 ml of 40 mg triamcinolone acetonide and 4 ml of 1% lidocaine DRUG

ultrasonography-guided suprascapular nerve block and intra-articular shoulder injection

Also known as: intra-articular shoulder injection

intraarticular shoulder injection; suprascapular verve block

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• unilateral stage 2-3 AC
• no shoulder trauma in the last 3 months
• no shoulder injections
• no bleeding disorder
• no history of malignancy
• no history of inflammatory disease
• Exlusion Criteria:
• malignancy
• inflammatory disease

Sponsors & Collaborators

• Hitit University: lead

Study Sites (1)

Hitit University

Çorum, 19030, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Bursitis

Interventions

Triamcinolone Acetonide; Lidocaine

Condition Hierarchy (Ancestors)

Joint Diseases; Musculoskeletal Diseases

Intervention Hierarchy (Ancestors)

Triamcinolone; Pregnadienes; Pregnanes; Steroids; Fused-Ring Compounds; Polycyclic Compounds; Steroids, Fluorinated; Acetanilides; Anilides; Amides; Organic Chemicals; Aniline Compounds; Amines

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Masking Details: double blind randomized controlled
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Specialist Doctor

Model Details: randomized, controlled trial

Study Record Dates

• First Submitted: June 1, 2023
• First Posted: June 18, 2023
• Study Start: January 21, 2023
• Primary Completion: April 24, 2023
• Study Completion: May 24, 2023
• Last Updated: June 18, 2023

Record last verified: 2023-06

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, SAP, ICF, CSR, ANALYTIC CODE
• Time Frame: 21/01/2023-24/05/2023

Locations

TU (1)